New Heart Drugs Come in More Expensive Than Expected

July 27, 2015

Reuters (Hirschler, 7/27) reported that the debate over whether modern drugs cost too much was brought to the forefront again due to “two of the most anticipated new heart drugs to be launched in recent years” being priced above analyst expectations. The drugs, “Praluent, made by Sanofi and Regeneron Pharmaceuticals, and Entresto from Novartis are both treatments that represent significant advances for millions of patients at risk of serious heart problems. But their positioning in the marketplace was always likely to be contentious since they offer more effective alternatives to very cheap, off-patent drugs.”